FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails

The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. | The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug.